Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 3/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.40 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19869937 | 1.00 | TLR9 (0.46) | TLR9TLR8TLR7KDM1ACHRNB2 | |
| SCHEMBL24556475 | 1.00 | TLR9 (0.46) | TLR9TLR8TLR7KDM1ACHRNB2 | |
| Hydrochloric Acid SCHEMBL19857606 | 0.99 | TLR9 (0.45) | TLR9TLR8TLR7KDM1ACHRNB2 | |
| Hydrochloric Acid SCHEMBL19857605 | 0.99 | TLR9 (0.45) | TLR9TLR8TLR7KDM1ACHRNB2 | |
| SCHEMBL19869978 | 0.80 | EGFR (0.38) | — | |
| SCHEMBL24556498 | 0.80 | EGFR (0.38) | — | |
| SCHEMBL24556500 | 0.80 | EGFR (0.38) | — | |
| SCHEMBL24556655 | 0.77 | TLR9 (0.44) | TLR9TLR8TLR7KDM1AROCK2 | |
| SCHEMBL24556644 | 0.77 | TLR9 (0.44) | TLR9TLR8TLR7KDM1AROCK2 | |
| SCHEMBL19871790 | 0.77 | TLR9 (0.45) | TLR9TLR8TLR7KDM1AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BRD9, BRD1, BRD2 | TLR9 2602/4885TLR8 4435/4885TLR7 2801/4885 |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BRD9, BRD1, BRD2 | TLR9 2312/4885TLR8 4354/4885TLR7 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.